🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 06/11/2023 | 379,27 | 387,42 | 379,27 | 385,76 | +2,54% | 2,15% | 1.999.000 |
| 03/11/2023 | 379,64 | 381,00 | 375,85 | 376,20 | -0,09% | 1,36% | 1.456.800 |
| 02/11/2023 | 370,23 | 376,84 | 367,73 | 376,55 | +1,95% | 2,46% | 1.138.000 |
| 01/11/2023 | 364,95 | 370,71 | 363,22 | 369,33 | +1,99% | 2,05% | 1.003.500 |
| 31/10/2023 | 355,92 | 363,10 | 353,13 | 362,11 | +1,30% | 2,80% | 987.700 |
| 30/10/2023 | 357,15 | 358,97 | 355,58 | 357,45 | +0,61% | 0,95% | 872.400 |
| 27/10/2023 | 360,61 | 362,31 | 353,76 | 355,28 | -1,66% | 2,37% | 910.700 |
| 26/10/2023 | 362,03 | 365,66 | 360,02 | 361,28 | -0,48% | 1,56% | 942.100 |
| 25/10/2023 | 369,21 | 370,00 | 360,91 | 363,04 | -1,72% | 2,46% | 958.000 |
| 24/10/2023 | 365,93 | 371,02 | 364,58 | 369,38 | +0,47% | 1,76% | 997.300 |
| 23/10/2023 | 363,25 | 368,15 | 360,47 | 367,66 | +1,60% | 2,11% | 1.566.000 |
| 20/10/2023 | 365,72 | 367,48 | 361,59 | 361,86 | -0,81% | 1,61% | 1.389.400 |
| 19/10/2023 | 367,55 | 369,67 | 361,72 | 364,80 | -0,75% | 2,16% | 1.514.700 |
| 18/10/2023 | 372,43 | 375,65 | 366,68 | 367,55 | -1,59% | 2,41% | 1.516.600 |
| 17/10/2023 | 373,25 | 375,93 | 372,58 | 373,50 | -0,13% | 0,90% | 1.674.500 |
| 16/10/2023 | 372,12 | 374,45 | 371,05 | 374,00 | +0,81% | 0,91% | 1.767.600 |
| 13/10/2023 | 368,57 | 372,78 | 367,18 | 371,00 | +0,82% | 1,52% | 1.360.700 |
| 12/10/2023 | 366,37 | 370,64 | 365,53 | 368,00 | +0,75% | 1,39% | 1.303.800 |
| 11/10/2023 | 361,46 | 365,27 | 359,14 | 365,25 | +1,30% | 1,70% | 1.184.600 |
| 10/10/2023 | 354,46 | 362,40 | 352,63 | 360,57 | +1,51% | 2,76% | 966.600 |
| 09/10/2023 | 361,22 | 363,48 | 353,62 | 355,20 | -1,50% | 2,73% | 1.429.300 |
| 06/10/2023 | 354,61 | 362,99 | 352,25 | 360,62 | +1,54% | 3,03% | 1.147.900 |
| 05/10/2023 | 353,38 | 355,77 | 351,23 | 355,14 | +0,61% | 1,28% | 670.900 |
| 04/10/2023 | 346,72 | 353,70 | 345,10 | 352,97 | +2,27% | 2,48% | 895.500 |
| 03/10/2023 | 345,28 | 347,79 | 341,85 | 345,15 | -0,77% | 1,72% | 784.700 |
| 02/10/2023 | 346,76 | 348,07 | 342,62 | 347,83 | +0,03% | 1,57% | 750.200 |
| 29/09/2023 | 351,94 | 354,18 | 347,26 | 347,74 | -1,35% | 1,97% | 896.800 |
| 28/09/2023 | 351,14 | 354,52 | 350,63 | 352,50 | +0,82% | 1,11% | 578.900 |
| 27/09/2023 | 351,16 | 352,91 | 347,52 | 349,65 | -0,58% | 1,53% | 860.600 |
| 26/09/2023 | 350,00 | 352,54 | 349,17 | 351,69 | +0,29% | 0,96% | 633.600 |